BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12970394)

  • 1. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.
    Okamoto T; Niu R; Yamada S
    Mol Hum Reprod; 2003 Oct; 9(10):569-75. PubMed ID: 12970394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
    Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
    Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
    Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
    Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of gelatinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-2 and TIMP-3) in the chicken ovary in relation to follicle development and atresia.
    Hrabia A; Wolak D; Kwaśniewska M; Kieronska A; Socha JK; Sechman A
    Theriogenology; 2019 Feb; 125():268-276. PubMed ID: 30481606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
    Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
    Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human fetal testis and ovary.
    Robinson LL; Sznajder NA; Riley SC; Anderson RA
    Mol Hum Reprod; 2001 Jul; 7(7):641-8. PubMed ID: 11420387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues.
    Kikkawa F; Tamakoshi K; Nawa A; Shibata K; Yamagata S; Yamagata T; Suganuma N
    Cancer Lett; 1997 Nov; 120(1):109-15. PubMed ID: 9570393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
    Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
    Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
    Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.
    Ripley D; Tunuguntla R; Susi L; Chegini N
    Int J Gynecol Cancer; 2006; 16(5):1794-800. PubMed ID: 17009974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
    Maeta H; Ohgi S; Terada T
    Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
    Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) during the course of experimental necrotizing herpetic keratitis.
    Yang YN; Bauer D; Wasmuth S; Steuhl KP; Heiligenhaus A
    Exp Eye Res; 2003 Aug; 77(2):227-37. PubMed ID: 12873454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.